SS Innovations International (NASDAQ: SSII) is advancing its SSi Mantra surgical robotic platform from an established base in India into international markets, with growth reflected in both revenue and system installations. Second-quarter revenue increased 39.4% year over year to $13.9 million, while the company installed 30 systems during the quarter, bringing its total installed base to 224 systems across 12 countries and more than 12,000 cumulative procedures as of June 30, 2026.
The company supports a range of specialties, including cardiac, urology, gynecology, general and thoracic surgery, and is also developing telesurgery capabilities. SSII’s growth opportunity extends beyond its current markets, with the company pursuing U.S. FDA 510(k) clearance and European CE marking that could substantially broaden its addressable market. To view the full article, visit https://nnw.fm/zbfTI.
The expansion matters because surgical robotics has historically been dominated by a few high-cost players, leaving many hospitals and patients without access to minimally invasive robotic options. SS Innovations aims to change that by making robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the proprietary SSi Mantra system and a comprehensive suite of SSi Mudra surgical instruments, which support a variety of procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
For investors and industry observers, the key takeaway is that SSII is not just growing revenue but also deepening its clinical footprint. The latest news and updates relating to SSII are available in the company’s newsroom at https://nnw.fm/SSII. The company’s progress comes as the global surgical robotics market continues to evolve, with demand rising for systems that can support complex procedures while reducing costs. If SSII secures FDA clearance and CE marking, it could compete more directly in the world’s largest healthcare markets, potentially accelerating adoption and opening new revenue streams.
The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
For the broader healthcare industry, SSII’s trajectory signals that cost-effective robotic surgery is becoming a viable export from emerging markets to the world. As the company scales installations and procedures, it could pressure competitors to innovate on price and accessibility, ultimately benefiting hospitals and patients seeking advanced surgical care. The coming regulatory decisions in the U.S. and Europe will be critical milestones to watch.
